Generation of RAGE-1 and MAGE-9 peptide-specific cytotoxic T-Lymphocyte lines for transfer in patients with renal cell carcinoma
✍ Scribed by Nicole Oehlrich; Gerard Devitt; Michael Linnebacher; Yvette Schwitalle; Sonja Groβkinski; Stefan Stevanovic; Margot Zöller
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- French
- Weight
- 342 KB
- Volume
- 117
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Renal cell carcinomas (RCCs) are supposed to be immunogenic, and several clinical trials of immunotherapy using tumor lysate‐pulsed dendritic cells (DCs) have been performed. We report on the generation of RAGE‐1 and MAGE‐9 peptide‐specific CTL lines. RAGE‐1 and MAGE‐9 are expressed in 56% and 38% of RCCs. Seven MAGE‐9‐ and 13 RAGE‐1‐derived peptides were found to be immunogenic in the context of the HLA‐A*0201 MHC. CTLs were generated by coculture with peptide‐pulsed, activated B cells, which were easily generated in great quantities and displayed functional activity for a prolonged period of time. MAGE‐9 and RAGE‐1 peptide‐specific CTL lines were strictly peptide‐specific and displayed high cytotoxic activity not only against peptide‐loaded T2 cells but also against HLA‐A*0201‐positive RCC lines, which naturally express MAGE‐9, RAGE‐1 or both. Thus, B cells are well suited as APCs for the generation of large numbers of tumor peptide‐specific CTLs for adoptive transfer. MAGE‐9 as well as RAGE‐1 may well provide suitable targets for immunotherapy of RCC. © 2005 Wiley‐Liss, Inc.